Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

See all formats and pricing
Volume 45, Issue 5 (May 2007)


Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results

Francesca Di Serio
  • 1Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy
/ Antonietta Fontana
  • 2Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy
/ Michele Loizzi
  • 3Department of Thoracic Surgery, University Hospital of Bari, Bari, Italy
/ Giuseppe Capotorto
  • 4Department of Thoracic Surgery, University Hospital of Bari, Bari, Italy
/ Piera Maggiolini
  • 5Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy
/ Ernesto Mera
  • 6Department of Occupational Medicine, University Hospital of Bari, Bari, Italy
/ Lucia Bisceglia
  • 7Section of Environmental and Occupational Epidemiology and Ergonomics, University Hospital of Bari, Bari, Italy
/ Raffaele Molinini
  • 8Department of Occupational Medicine, University Hospital of Bari, Bari, Italy
Published Online: 2007-05-07 | DOI: https://doi.org/10.1515/CCLM.2007.112


Background: Studies have suggested that soluble mesothelin-related protein (SMRP) can be used as a serum marker of malignant mesothelioma.

Methods: We assessed the analytical performance of the Mesomark (Fujirebio Diagnostic) two-step ELISA on an automated analyser and performed a preliminary clinical evaluation. The precision of the assay and the in vitro effect of interfering substances on SMRP concentrations were investigated. The serum marker was analysed in 109 healthy subjects never exposed to asbestos, 26 healthy subjects exposed to asbestos, 33 patients with asbestosis, 33 with asbestos-related pleural plaques, 10 with non-malignant pleural diseases, 30 with lung cancer and 24 with histological diagnosis of pleural mesothelioma.

Results: Using the International Mesothelioma Interest Group classification, there were nine stage IV, two stage III, four stage II and nine stage I patients. SMRP concentrations of 4.75, 11.0 and 14 nmol/mL showed a total imprecision of 3.5%, 3.1% and 3.8%. The detection limit was 0.035 nmol/mL; the mean SMRP concentration of 0.63 nmol/mL was associated with a coefficient of variation of 10%. There was no effect (p>0.05) of interfering substances. Serum samples from patients with established pleural mesothelioma had significantly higher (p<0.05) concentrations of SMRP than control healthy and patient groups.

Conclusions: SMRP measured on automated systems could be useful for the diagnosis of mesothelioma in routine clinical practice.

Clin Chem Lab Med 2007;45:634–8.

Keywords: mesothelioma; soluble mesothelin-related peptides

About the article

Corresponding author: Francesca Di Serio, Department of Clinical Pathology I, University Hospital of Bari, Piazza Giulio Cesare N. 11, 70124 Bari, Italy Phone: +39-080-5592629, Fax: +39-080-5592124,

Received: 2006-11-23

Accepted: 2007-01-29

Published Online: 2007-05-07

Published in Print: 2007-05-01

Citation Information: Clinical Chemical Laboratory Medicine, ISSN (Online) 14346621, ISSN (Print) 14374331, DOI: https://doi.org/10.1515/CCLM.2007.112. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Heather H. Nelson, Lindsay M. Almquist, Jessica L. LaRocca, Silvia L. Plaza, Geralyn M. Lambert-Messerlian, David J. Sugarbaker, Raphael Bueno, John J. Godleski, Carmen J. Marsit, Brock C. Christensen, and Karl T. Kelsey
Epigenetics, 2011, Volume 6, Number 8, Page 1029
Petr Jakubec, Daniela Pelclova, Petra Smolkova, Vitezslav Kolek, and Marie Nakladalova
Biomedical Papers, 2014
Kevin Hollevoet, Kristiaan Nackaerts, Joël Thimpont, Paul Germonpré, Lionel Bosquée, Paul De Vuyst, Catherine Legrand, Eliane Kellen, Yoshiro Kishi, Joris R. Delanghe, and Jan P. van Meerbeeck
American Journal of Respiratory and Critical Care Medicine, 2010, Volume 181, Number 6, Page 620
Ling Luo, Huan-Zhong Shi, Qiu-Li Liang, Jing Jiang, Shou-Ming Qin, and Jing-Min Deng
Respiratory Medicine, 2010, Volume 104, Number 1, Page 149
Steven Chuan-Hao Kao, Glen Reid, Nico van Zandwijk, Douglas W Henderson, and Sonja Klebe
Pathology, 2011, Volume 43, Number 3, Page 201
Eun-Kee Park, Paul S. Thomas, Jenette Creaney, Anthony R. Johnson, Bruce W. Robinson, and Deborah H. Yates
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 6
Giorgio Vittorio Scagliotti and Giovanni Selvaggi
Oncology Reviews, 2007, Volume 1, Number 2, Page 91
Zhong-Qian Li, Thorsten Verch, and W Jeffrey Allard
Expert Opinion on Medical Diagnostics, 2007, Volume 1, Number 1, Page 137

Comments (0)

Please log in or register to comment.
Log in